What's behind Gilead Sciences's latest 3.6% stock surge?

Traders Union
All News
Stocks
Gilead surges 3.60% today to $153.24

Highlights

Gilead Sciences second-quarter revenue grew 10.6% year over year to $7.80 billion despite reporting a GAAP net loss tied to research project acquisitions.
The company secured a $65 million upfront deal and invested a further $25 million with Vir Biotechnology to advance new immuno-oncology therapies.
Shares of Gilead Sciences trade above key moving averages with bullish technical momentum, forecast to consolidate between $147.91 to $157.02 with buyer dominance but early signals of fatigue.

Cash flow strength offsets net loss amid R&D spending and deal

Gilead Sciences reported second-quarter revenue of $7.80 billion, a 10.6% year-over-year increase. The company entered a collaboration with Vir Biotechnology, paying $65 million upfront and investing an additional $25 million to develop novel immuno-oncology therapies. Free cash flow of $3.43 billion for the quarter also comfortably covered its dividend payout, even as a GAAP net loss was reported due to research project acquisitions.

Anton Kharitonov, expert at Traders Union, sees Gilead’s strong quarter and upbeat revenue as offset by its GAAP net loss and overbought signs. He notes bullish momentum is clear, but questions sustainability given early oscillator fatigue and risks from aggressive expansion in oncology. Moving averages and MACD suggest ongoing strength, yet the combination of overbought BBP and a pullback in Stochastic RSI raises concern. He also highlights that hefty upfront payments in the Vir deal add pressure to deliver results. "While short-term sentiment favors buyers, I remain cautious as weakening oscillators may signal a pullback ahead."

Viktoras Karapetjanc, expert at Traders Union, highlights Gilead’s robust revenue growth and substantial free cash flow as further strengthening its outlook. He sees the Vir partnership as unlocking new strategic potential and reinforcing Gilead’s innovation leadership in oncology. With technicals confirming a clear uptrend, he believes the bullish structure remains intact despite minor short-term volatility. "Gilead’s fundamentals and confident execution point toward further growth — the market offers multiple setups for long-term investors here."

Parshwa Turakhiya, analyst, notes strong sentiment in GILD after the collaborative headlines and healthy revenue. Technicals show buyers firmly in control above key moving averages, but oscillators reveal mixed moods — momentum is evident, yet some short-term fatigue appears. He sees a consolidation zone with opportunities for agile trading if price breaks above $157.02 or dips below $147.91. "Short-term swings are shaping up — I would watch for quick setups as traders react to new highs or any signs of reversal."

Bullish momentum across averages as oscillators show mixed signals

Gilead Sciences is trading well above its 20-day, 50-day, and 200-day moving averages ($149.04, $145.44, $137.55 respectively), indicating ongoing bullish momentum across short-, medium-, and long-term trends. The Ichimoku Kijun at $148.33 provides nearby support, with the next resistance and support at $157.02 and $152.26 respectively. Momentum indicators are largely positive: MACD and ADX both signal 'Buy,' while RSI is at 51.46, favoring continued gains. However, Stochastic RSI is pulling back, CCI is neutral, and BBP is strongly positive at 2.85, flagging potential overbought risk. The Awesome Oscillator supports the broader bullish trend, as the stock surged near its intraday high with volatility at 1.59%. Most signals confirm strong buying pressure, though early signs of fatigue are present in some oscillators.

Earlier, analysts noted that Gilead Sciences was constrained by persistent technical resistance and bearish momentum despite strong operational performance and the removal of a major legal risk. The current move above key technical levels and fresh momentum signals mark a notable shift, making the $157.02 resistance area a critical threshold to monitor for confirmation of continued upside.

Source of Data: GILD Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.